Novartis' MONALEESA-7 Kisqali (ribociclib succinate) study demonstrated statistically significant improvement in overall survival in pre- and peri-menopausal women with HR+/HER2- advanced breast cancer

Novartis

2 November 2020 - Novartis Pharmaceuticals Canada is pleased to announce that statistically significant overall survival  results for Kisqali (ribociclib succinate) in combination therapy have now been approved within the Kisqali Product Monograph. 

The pivotal Phase 3 MONALEESA-7 trial evaluated Kisqali with endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to placebo plus endocrine therapy, in pre- and peri-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.

Read Novartis press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada